Richard J. Bold
Expertise in
19
conditions

Dr. Richard J. Bold

Surgical Oncology | General Surgery
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
19
conditions
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Bold is a Surgical Oncologist and a General Surgeon in Scottsdale, Arizona. Dr. Bold is highly rated in 19 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Breast Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Mastectomy.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Surgical Oncology
General Surgery
Licenses
Surgery in CA
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Other
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
View 8 Less Clinical Trials

112 Total Publications

Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies.
Genetically proxied risk and protective factors for pancreatic cancer: a systematic review and meta-analysis of Mendelian randomization studies.
Journal: Journal of gastrointestinal oncology
Published: April 20, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Barbara A. Pockaj
General Surgery | Surgical Oncology
Expertise in
9
conditions
Dr. Barbara A. Pockaj
General Surgery | Surgical Oncology

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
 (10.7 miles away)
800-603-0558
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Barbara Pockaj is a General Surgeon and a Surgical Oncologist in Phoenix, Arizona. Dr. Pockaj is highly rated in 9 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Melanoma, Mastectomy, and Lymphadenectomy. Dr. Pockaj is currently accepting new patients.

Zhi V. Fong
Expertise in
6
conditions
Dr. Zhi V. Fong
Surgical Oncology | General Surgery
Expertise in
6
conditions
Dr. Zhi V. Fong
Surgical Oncology | General Surgery

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (0.1 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zhi Fong is a Surgical Oncologist and a General Surgeon in Scottsdale, Arizona. Dr. Fong is highly rated in 6 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Gastrointestinal Fistula, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Gallbladder Removal.

Expertise in
24
conditions
Dr. Mark I. Gimbel
Surgical Oncology | General Surgery
Expertise in
24
conditions
Dr. Mark I. Gimbel
Surgical Oncology | General Surgery

Banner Cancer Center Specialists LLC

1900 N Higley Rd, 
Gilbert, AZ 
 (14.4 miles away)
480-543-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Gimbel is a Surgical Oncologist and a General Surgeon in Gilbert, Arizona. Dr. Gimbel is highly rated in 24 conditions, according to our data. His top areas of expertise are Melanoma, Alveolar Soft Part Sarcoma, Bone Tumor, Hernia Surgery, and Small Bowel Resection. Dr. Gimbel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bold's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile